159 related articles for article (PubMed ID: 23772664)
1. BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Sun X; He Y; Mao C; Zhu L; Qin X; Huang S
Leuk Lymphoma; 2014 Feb; 55(2):435-8. PubMed ID: 23772664
[No Abstract] [Full Text] [Related]
2. Chronic myelogenous leukemia in accelerated phase.
Huang Q
Arch Pathol Lab Med; 2005 May; 129(5):710. PubMed ID: 15859653
[No Abstract] [Full Text] [Related]
3. Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Kashimura M; Ohyashiki K
Leuk Res; 2010 Aug; 34(8):e213-4. PubMed ID: 20299093
[No Abstract] [Full Text] [Related]
4. PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
Baba SM; Azad NA; Shah ZA; Afroze D; Pandith AA; Jan A; Aziz SA; Dar FA
Asian Pac J Cancer Prev; 2016; 17(4):1999-2006. PubMed ID: 27221887
[TBL] [Abstract][Full Text] [Related]
5. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Godley LA
Leuk Lymphoma; 2009 Jun; 50(6):871-2. PubMed ID: 19479615
[No Abstract] [Full Text] [Related]
6. Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
Gutiérrez NC; García JL; Chillón C; Muntión S; González M; Hernández JM
Haematologica; 1999 Jan; 84(1):88-90. PubMed ID: 10091399
[No Abstract] [Full Text] [Related]
7. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
Porosnicu M; Nimmanapalli R; Nguyen D; Worthington E; Perkins C; Bhalla KN
Leukemia; 2001 May; 15(5):772-8. PubMed ID: 11368438
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
10. p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
Cividin M; Brizard F; Sorel N; Renaud M; Guilhot F; Brizard A
Leuk Res; 2004 Jan; 28(1):97-9. PubMed ID: 14630086
[TBL] [Abstract][Full Text] [Related]
11. [Biclonal co-existence of t(15;17) and t(9;22) chromosomal abnormalities in acute promyelocytic leukemia].
Takahashi H; Sakai R; Hattori Y; Ohshima R; Hagihara M; Kuwabara H; Ishigatsubo Y; Fujisawa S
Rinsho Ketsueki; 2011 Jan; 52(1):37-40. PubMed ID: 21378481
[TBL] [Abstract][Full Text] [Related]
12. A case of cryptic acute promyelocytic leukemia.
Aventín A; Mateu R; Martino R; Colomer D; Bordes R
Leukemia; 1998 Sep; 12(9):1490-1. PubMed ID: 9737701
[No Abstract] [Full Text] [Related]
13. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Zhang X; Pan J
Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
[No Abstract] [Full Text] [Related]
14. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J
Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138
[No Abstract] [Full Text] [Related]
15. Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Pieńkowska-Grela B; Rygier J; Woroniecka R; Grygalewicz B; Pastwińska A; Krawczyk P; Ceglerek B; Seferyńska I; Sikorska A; Konopka L
Leuk Lymphoma; 2009 Jun; 50(6):952-65. PubMed ID: 19479611
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of chronic myeloid leukemia in chronic phase].
Matsumura I
Rinsho Ketsueki; 2014 Oct; 55(10):1853-9. PubMed ID: 25297749
[No Abstract] [Full Text] [Related]
17. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome and proteome analyses of drug interactions with natural products.
Fang H; Wang K; Zhang J
Curr Drug Metab; 2008 Dec; 9(10):1038-48. PubMed ID: 19075620
[TBL] [Abstract][Full Text] [Related]
19. PML/RAR alpha APL with undifferentiated morphology and stem cell immunophenotype.
Foley R; Soamboonsrup P; Kouroukis T; Leber B; Carter RF; Sunisloe L; Chorneyko K; Neame PB
Leukemia; 1998 Sep; 12(9):1492-3. PubMed ID: 9737702
[No Abstract] [Full Text] [Related]
20. Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Kai T; Kimura H; Shiga Y; Ogawa K; Sato H; Maruyama Y
Int J Hematol; 2006 May; 83(4):337-40. PubMed ID: 16757435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
